Hetero Labs Limited Sitagliptin Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Sitagliptin Export Records India — #4 Exporter, 56 Shipments, $2.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Sitagliptin

India Pharmaceutical Trade Intelligence

$75.8M309 Suppliers121 CountriesHS 30049099

ExportsIndia → CANADA11.6%India → MEXICO11.1%

ImportsCANADA → India$43.8K NETHERLANDS → India$23.2K

#1 Buyer: YILMAZ TRANSPORT

Hetero Labs Limited — Sitagliptin Exporter #4 | $2.8M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Sitagliptin Exporter Profile

Indian Pharmaceutical Exporter · #4 for Sitagliptin · $2.8M export value · DGFT Verified

Hetero Labs Limited is the #4 Indian exporter of Sitagliptin with $2.8M in export value and 56 verified shipments. Hetero Labs Limited holds a 3.7% market share in Sitagliptin exports across 7 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Sitagliptin Export Profile: Buyers & Destinations

Hetero Labs Limited Sitagliptin export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Sitagliptin?

Country	Value	Shipments	Share
MEXICO	$1.6M	32	86.0%
UNITED KINGDOM	$166.8K	7	9.1%
NETHERLANDS	$72.7K	4	3.9%
MALTA	$9.6K	2

Who Are the Top Buyers of Sitagliptin from Hetero Labs Limited?

Buyer	Country	Value	Orders
XXAROXXPHAXXA XXA XX C XX	MEXICO	$1.0M	20
XXAROXXPHAXXA SXX DXXC VX	MEXICO	$583.4K	12
XXAROXXLIMXXED	UNITED KINGDOM	$166.8K	7
XXAROXXPHAXXA BXX	NETHERLANDS	$51.9K	3
XXAROXXPHAXXA GXXH	NETHERLANDS	$20.7K	1
XXUMAXXPHAXXA GXXH ANDXXO XXNERXXA KX	MALTA	$9.6K	2
TO THE ORDER OF	BOTSWANA	$8.5K	3
M/S. MAKIZ PHARMA LIMITED	RUSSIA	$104	2
M S TO THE ORDER OFCAMBER FARMACEUTICA LIMITED A	BRAZIL	$0	6

Hetero Labs Limited supplies Sitagliptin to 9 buyers globally. The largest buyer is XXAROXXPHAXXA XXA XX C XX (MEXICO), followed by XXAROXXPHAXXA SXX DXXC VX (MEXICO) and XXAROXXLIMXXED (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Sitagliptin Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
SITAGLIPTIN / METFORMIN HCL 50/850MG	$700.0K	14
SITAGLIPTIN 100MG TABLETS (2X14'S)	$533.4K	11
SITAGLIPTIN PHOSPHATE 100MG TABLETS	$150.0K	3
SITAGLIPTIN/METFORMIN HCL	$100.0K	2
SITAGLIPTIN/METFORMIN HCL 50/850MG	$100.0K	2
SITAGLIPTIN 100MG TABLETS	$70.7K	2
SITAGLIPTINE PHOSPHATE 100MG TABLETS	$50.0K	1
SITAGLIPTINE PHOSPHATE 50MG TABLETS	$47.1K	2
SITAGLIPTIN 50MG TABLETS (2X14'S)	$24.4K	1
SITAGLIPTIN 25MG TABLETS (2X14'S)	$24.3K	4

Hetero Labs Limited exports 23 distinct Sitagliptin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is SITAGLIPTIN / METFORMIN HCL 50/850MG with 14 shipments worth $700.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.

How Does Hetero Labs Limited Compare to Nearest Sitagliptin Exporters?

Exporters ranked immediately above and below #4 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
8	MSN LABORATORIES PRIVATE LIMITED	$3.2M	78	1	$41.6K
9	AUROBINDO PHARMA LIMITED	$2.9M	63	4	$46.4K
4	HETERO LABS LIMITED ★	$2.8M	56	7	$50.0K
5	FREDUN PHARMACEUTICALS LTD	$2.8M	56	1	$50.0K
11	BETA DRUGS LIMITED	$2.4M	85	1	$28.6K

Hetero Labs Limited ranks #4 among 309 Indian Sitagliptin exporters. Average shipment value of $50.0K compared to the market average of $149.3K. The closest competitors by value are MSN LABORATORIES PRIVATE LIMITED and AUROBINDO PHARMA LIMITED.

Which Indian Ports Ship Sitagliptin Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	772	14.4%
DELHI AIR CARGO ACC (INDEL4)	739	13.8%
SAHAR AIR	735	13.7%
DELHI AIR	513	9.6%
NHAVA SHEVA SEA (INNSA1)	217	4.0%
HYDERABAD AIR	213	4.0%
Bombay Air	196	3.7%
HYDERABAD ACC (INHYD4)	191	3.6%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Sitagliptin Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Sitagliptin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 56 individual customs records matching Hetero Labs Limited exporting Sitagliptin, covering 23 formulations to 7 countries via 9 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 121+ countries, 575+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Sitagliptin

Sitagliptin

Hetero Labs Limited — Sitagliptin Exporter Profile

Hetero Labs Limited — Sitagliptin Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Sitagliptin?

Who Are the Top Buyers of Sitagliptin from Hetero Labs Limited?

What Is India's Total Sitagliptin Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Sitagliptin Exports?

How Does Hetero Labs Limited Compare to Other Indian Sitagliptin Exporters?

What Sitagliptin Formulations Does Hetero Labs Limited Export?

Regulatory Requirements: Exporting Sitagliptin to Key Markets

Mexico — COFEPRIS

United Kingdom — MHRA

How Does Hetero Labs Limited Compare to Nearest Sitagliptin Exporters?

Which Indian Ports Ship Sitagliptin Exports?

Sitagliptin — Export Intelligence Video

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Sitagliptin Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Sitagliptin Export Data from Hetero Labs Limited

Sitagliptin Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source